Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions-Reference-Cited by-同舟云学术

Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions

Published:2014-12-18 Issue:26 Volume:124 Page:3991-3995
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Levade Marie¹²,David Elodie²,Garcia Cédric²,Laurent Pierre-Alexandre¹,Cadot Sarah²,Michallet Anne-Sophie³,Bordet Jean-Claude⁴,Tam Constantine⁵,Sié Pierre¹²,Ysebaert Loïc⁶,Payrastre Bernard¹²

Affiliation:

1. INSERM, U1048 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France;

2. Laboratoire d’Hématologie Centre Hospitalier Universitaire de Toulouse, Toulouse, France;

3. Service d’Hématologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France;

4. Laboratoire d’Hémostase, Centre Hospitalier Universitaire Hôpital Edouard Herriot, Lyon, France;

5. Department of Hematology, Peter MacCallum Cancer Center, East Melbourne, VIC, Australia; and

6. Service d’Hématologie Institut Universitaire du Cancer de Toulouse-Oncopôle, Toulouse, France

Abstract

Key Points Ibrutinib affects collagen and VWF-mediated platelet activation. The bleeding diathesis correlates with defects in collagen-induced platelet aggregation and firm adhesion on VWF at arterial shear rate.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/26/3991/1466031/3991.pdf

Reference21 articles.

1. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.;Ponader;Blood,2012

2. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.;Herman;Blood,2011

3. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.;Honigberg;Proc Natl Acad Sci USA,2010

4. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.;Byrd;N Engl J Med,2013

5. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.;Wang;N Engl J Med,2013

Cited by 270 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of infectious morbidity due to BTK inhibitors in indolent B-cell lymphomas: latest research findings and systematic analysis;Expert Opinion on Pharmacotherapy;2024-07-23

2. New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modeling;PLOS Medicine;2024-07-22

3. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia;Current Hematologic Malignancy Reports;2024-03-27

4. Spontaneous Hyphema during Ibrutinib Treatment in a CLL Patient;Case Reports in Hematology;2023-12-14

5. Management of Toxicities of BTK Inhibitors in B-Cell Malignancies;Journal of the National Comprehensive Cancer Network;2023-11-25